- Category
- Small (2024-25)
- Udyam number
- UDYAM-GJ-20-0028039

About Aptus Pharma Limited
Data last updated:
Aptus Pharma Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the wholesale trading and distribution segment of the trading and commerce sector. It was incorporated on 12 August 2010 and has been in existence for over 16 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24230GJ2010PLC061957. Its GSTIN is 24AAICA7890D1ZM (Gujarat). It is a listed company as per MCA records. Its shares are listed on BSE: 544529.
The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹17.15 Cr. It is led by directors including Tejash Maheshchandra Hathi (Managing Director) and Sejal Harit Palan.
Its last annual general meeting (AGM) was held on 14 September 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Harikrupa Logistic Park, Ahmedabad, Gujarat.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹46.57 Cr, a growth of 89.6% compared to the previous year. For the same year it recorded a net profit of ₹4.6 Cr (net margin 9.9%) and EBITDA of ₹7.43 Cr (EBITDA margin 16%). The net worth stands at ₹23.35 Cr (up 235% YoY). Total assets are valued at ₹30.89 Cr (up 75.8% YoY).
The company has about 28 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Aptus Pharmaceuticals. As per MCA filings, the company has open charges of ₹12.63 Cr and satisfied charges of ₹3 Cr on record. Court records list 2 cases involving the company, including 2 filed by the company. The company has 11 deals on record (10 market trades, 1 ipo); the latest was in December 2025. Its 4 peer companies in the Pharma industry (Formulations), with the same principal business activity (wholesale trading) are compared by revenue, 3 larger and 1 smaller; the largest is Us Amino Private Limited with revenue of ₹24.84 Cr.
Aptus Pharma Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-20-0028039). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aptus-pharma.com.
Company details
CIN history
Aptus Pharma has one previous CIN (Corporate Identification Number): U24230GJ2010PTC061957. The current CIN is U24230GJ2010PLC061957, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230GJ2010PLC061957 | Current |
| U24230GJ2010PTC061957 | Previous |
Recognitions & Rankings of Aptus Pharma
Contact details
Aptus Pharma Limited's registered office is in Ahmedabad, Gujarat.
- Registered AddressAshutosh Buildcon Opp. Slok 2, Nr. Harikrupa Logistic Park Aslali, Ahmedabad, Gujarat, India – 382427
- IndustryTrading, Wholesale, Other Wholesale
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Aptus Pharma operates one associated brand: Aptus Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Limited information available | aptuspharma.com |
Business activity
The main business activity of Aptus Pharma is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Aptus Pharma Limited, buy the company report.
Financials of Aptus Pharma Limited
FY 2025-26 filings availableAptus Pharma Limited reported revenue of ₹46.57 Cr (up 89.6% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 46.57 | 24.56 | 17.86 | 13.90 |
| Revenue growth | +89.6% | +37.5% | +28.5% | - |
| EBITDA | 7.43 | 4.84 | 1.55 | 0.62 |
| EBITDA margin | +16.0% | +19.7% | +8.7% | +4.5% |
| Profit before tax | 6.35 | 4.18 | 1.13 | 0.30 |
| Net profit | 4.60 | 3.09 | 0.81 | 0.20 |
| Net profit margin | +9.9% | +12.6% | +4.5% | +1.4% |
| EPS (₹) | 6.73 | 6.20 | 26.60 | 6.48 |
| Balance sheet | ||||
| Total assets | 30.89 | 17.57 | 7.24 | 3.29 |
| Net worth | 23.35 | 6.97 | 1.77 | 0.97 |
| Total debt | 7.18 | 10.36 | 5.31 | 2.22 |
| Cash & bank | 1.03 | 5.21 | 0.91 | 0.54 |
| Net working capital | 22.59 | 15.39 | 5.53 | 2.72 |
| Cash flow | ||||
| Cash from operations | (5.60) | (1.84) | (2.17) | (0.18) |
| Cash from investing | (6.37) | (0.54) | (0.30) | (0.35) |
| Cash from financing | 7.79 | 6.68 | 2.86 | 0.81 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 46.57 | 24.56 | 17.86 | 13.90 |
| Revenue growth | +89.6% | +37.5% | +28.5% | - |
| Other income | 0.13 | 0.08 | 0.03 | 0.00 |
| Total expenses | 39.14 | 19.72 | 16.31 | 13.28 |
| Employee cost | 5.21 | 3.57 | 2.31 | 1.57 |
| EBITDA | 7.43 | 4.84 | 1.55 | 0.62 |
| EBITDA margin | +16.0% | +19.7% | +8.7% | +4.5% |
| Depreciation | 0.41 | 0.27 | 0.21 | 0.18 |
| Interest | 0.80 | 0.47 | 0.24 | 0.14 |
| Profit before tax | 6.35 | 4.18 | 1.13 | 0.30 |
| Tax | 1.75 | 1.09 | 0.32 | 0.10 |
| Net profit | 4.60 | 3.09 | 0.81 | 0.20 |
| Net profit margin | +9.9% | +12.6% | +4.5% | +1.4% |
| EPS (₹) | 6.73 | 6.20 | 26.60 | 6.48 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 6.86 | 5.00 | 0.30 | 0.30 |
| Reserves & surplus | 16.49 | 1.97 | 1.47 | 0.67 |
| Shareholders' funds (net worth) | 23.35 | 6.97 | 1.77 | 0.97 |
| Secured loans | 4.66 | 5.49 | 1.58 | 0.33 |
| Unsecured loans | 2.52 | 4.87 | 3.73 | 1.89 |
| Total debt | 7.18 | 10.36 | 5.31 | 2.22 |
| Total liabilities | 30.89 | 17.57 | 7.24 | 3.29 |
| Assets | ||||
| Gross block | 4.04 | 1.86 | 1.24 | 0.91 |
| Net block | 2.76 | 0.99 | 0.64 | 0.52 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 13.57 | 7.06 | 3.43 | 2.30 |
| Sundry debtors | 18.76 | 5.64 | 3.35 | 2.40 |
| Cash & bank balances | 1.03 | 5.21 | 0.91 | 0.54 |
| Loans & advances | 1.88 | 1.83 | 0.62 | 0.41 |
| Total current assets | 35.24 | 19.74 | 8.31 | 5.65 |
| Total current liabilities | 12.65 | 4.35 | 2.78 | 2.93 |
| Net working capital | 22.59 | 15.39 | 5.53 | 2.72 |
| Total assets | 30.89 | 17.57 | 7.24 | 3.29 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 5.21 | 0.91 | 0.54 | 0.26 |
| Net cash from operating activities | (5.60) | (1.84) | (2.17) | (0.18) |
| Net cash from investing activities | (6.37) | (0.54) | (0.30) | (0.35) |
| Net cash from financing activities | 7.79 | 6.68 | 2.86 | 0.81 |
| Net change in cash | (4.19) | 4.30 | 0.38 | 0.28 |
| Closing cash | 1.03 | 5.21 | 0.91 | 0.54 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | +89.6% | +37.5% | +28.5% | - |
| EBITDA growth | +53.5% | +212.3% | +150.0% | - |
| PBT growth | +51.9% | +269.9% | +276.7% | +9997.0% |
| Net income growth | +48.9% | +281.5% | +305.0% | - |
| Revenue CAGR (3Y) | +49.6% | - | - | - |
| EBITDA CAGR (3Y) | +128.8% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +9.9% | +12.6% | +4.5% | +1.4% |
| Return on capital employed | +29.6% | +37.6% | +25.8% | +13.1% |
| Return on net worth | +30.5% | +70.9% | +58.4% | +19.6% |
| Debt / equity | 0.58 | 1.79 | 2.74 | 2.28 |
| Long-term debt / equity | 0.10 | 0.75 | 2.18 | 2.07 |
| Interest cover | 11.40 | 10.28 | 17.91 | 31.82 |
| Efficiency & per share | ||||
| Fixed asset turnover | 15.79 | 15.85 | 16.61 | 15.27 |
| Inventory turnover | 4.51 | 4.68 | 6.23 | 6.04 |
| Debtors turnover | 3.82 | 5.46 | 6.21 | 5.79 |
| EPS (₹) | 6.73 | 6.20 | 26.60 | 6.48 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 34.03 | 13.93 | 58.88 | 32.28 |
To see the full year-wise statements and ratios of Aptus Pharma Limited, buy the company report.
Board of directors of Aptus Pharma Limited
Aptus Pharma has 6 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Tejash Maheshchandra Hathi | Managing Director | 12 Aug 2010 | 16 Years 3 Months | Current |
| Sejal Harit Palan | Director | 06 Feb 2025 | 1 Years 9 Months | Current |
| Vikas Rambhai Jobanputra | Director | 06 Feb 2025 | 1 Years 9 Months | Current |
| Jyotiben Hasmukhbhai Chandarana | Director | 20 May 2024 | 2 Years 6 Months | Current |
| Chetan Shantilal Lalseta Also directs: SHMS Consultancy LLP, Shree Giriraj Lifecare Private Limited, Shree Giriraj Healthcare Private Limited and 1 more | Director | 17 Jan 2024 | 2 Years 10 Months | Current |
| Riddhish Natwarlal Tanna | Director | 17 Jan 2024 | 2 Years 10 Months | Current |
Peer comparison
Aptus Pharma Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Aptus Pharma Limitedthis company | ₹46.57 Cr (FY 2026) | ₹4.6 Cr | 9.9% | 89.6% | Ahmedabad, Gujarat, India | |
| Us Amino Private Limited | ₹24.84 Cr (FY 2024) | -3.0% | Mavli, Rajasthan, India | |||
| Zenacts Pharma Private Limited | ₹24.74 Cr (FY 2024) | -10.0% | Chandigarh, India | |||
| Pvpharma Healthcare Private Limited | ₹24.71 Cr (FY 2025) | 8.0% | Ahmedabad, Gujarat, India | |||
| Saviour Wellness Private Limited | ₹24.62 Cr (FY 2025) | 15.0% | New Delhi, Delhi, India |
To see the full peer comparison of Aptus Pharma Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 27 Jun 2026 | 101336736 | Others | ₹88 Lakh | Open | |
| 10 Apr 2026 | 101282364 | Others | ₹1.75 Cr | Open | |
| 27 Feb 2024 | 100880005 | Others | ₹10 Cr | Open | |
| 28 Apr 2023 | 100722274 | Hdfc Bank Limited | ₹2 Cr | Satisfied | |
| 15 Jul 2020 | 100361810 | Others | ₹5.85 Lakh | Satisfied |
To see the full charge records of Aptus Pharma Limited, buy the company report.
Total charge records: 7 View all charges
Deals & funding
Aptus Pharma Limited has 11 deals on record (10 market trades, 1 ipo); the latest was in December 2025.
Deals on record (5 of 11)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2025 | Market trade | ₹61.4 Lakh | Seller: Zeal Global Opportunities Fund |
| Dec 2025 | Market trade | ₹1.54 Cr | Seller: 31 Degrees North Fund I |
| Nov 2025 | Market trade | ₹60.6 Lakh | Seller: Zeal Global Opportunities Fund |
| Oct 2025 | Market trade | ₹30.8 Lakh | Seller: Pure Broking Private Limited |
| Sep 2025 | Market trade | ₹3.11 Cr | Buyer: Pure Broking Private Limited , 2 individuals |
To see the full deal history of Aptus Pharma Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Aptus Pharma Limited has 2 court cases on record: 2 filed by Aptus Pharma. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 2 | 0 | 0 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Writ petition | Filed by the company against Drugs Controller General of India & Anr. | Disposed |
| High Court of Delhi | Writ petition | Filed by the company against Union of India & Anr | Disposed |
To see the full case history of Aptus Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Aptus Pharma Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Aptus Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAICA7890D1ZM | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Aptus Pharma Limited, buy the company report.
Recent activity
Aptus Pharma Limited has 16 board changes on record since 2010: 6 appointments and 10 cessations. The latest: Chetan Shantilal Lalseta ceased to be Director on 09 Nov 2025.
22 earlier events are in the company report.
Frequently asked questions
Aptus Pharma is an active public limited company based in Ahmedabad, Gujarat, India. The company works in wholesale, within the trading industry. It was incorporated on 12 August 2010 (16+ years old) and is registered under CIN U24230GJ2010PLC061957. Listed on BSE: 544529.
Aptus Pharma reported revenue of ₹46.57 Cr for FY 2025-26 (up 89.6% YoY) based on standalone financials.
Aptus Pharma has 6 current directors:
- Tejash Maheshchandra Hathi - Managing Director
- Sejal Harit Palan - Director
- Vikas Rambhai Jobanputra - Director
- Jyotiben Hasmukhbhai Chandarana - Director
- Chetan Shantilal Lalseta - Director
- Riddhish Natwarlal Tanna - Director
The latest financial statements of Aptus Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 14 September 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of Aptus Pharma is 24AAICA7890D1ZM, registered in Gujarat.
The CIN (Corporate Identification Number) of Aptus Pharma is U24230GJ2010PLC061957. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Aptus Pharma is a listed company as per MCA records. Its shares are listed on BSE (code: 544529).
Aptus Pharma has 2 court cases on record: 2 filed by the company.
Aptus Pharma was incorporated on 12 August 2010, making it 16+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Aptus Pharma has 11 deals on record (10 market trades, 1 ipo); the latest was in December 2025.
The peers of Aptus Pharma by revenue are Us Amino Private Limited, Zenacts Pharma Private Limited, Pvpharma Healthcare Private Limited, Saviour Wellness Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (wholesale trading).

